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ABSTRACT. The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting 
potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are 
carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, 
we report preliminary structure-activity relationship studies of a previously disclosed non-acidic 
sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric 
agonists despite the absence of a carboxylate function. The preferred compounds showed full 
agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of 
these non-carboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal 
and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose 
tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice 
resulted in significantly increased insulin sensitivity and a moderate but significant reduction in 
bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking 
FFA4.   
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INTRODUCTION 
The free fatty acid receptor 4 (FFA4, also known as GPR120) has in recent years appeared as a 
new potential target for the treatment of metabolic diseases.1-7 The receptor was proposed as a 
possible antidiabetic and antiobesity target for the first time in 2005 when it was reported to be 
expressed in the intestinal tract and activated by dietary free fatty acids to stimulate incretin 
secretion,8 although this property of the receptor remains controversial.9 FFA4 was subsequently 
found to also be expressed in macrophages, liver and adipose tissue, and to mediate anti-
inflammatory and insulin sensitizing effects.10 The report that mice lacking FFA4 develop 
obesity, insulin intolerance and fatty liver when fed a high-fat diet and that a human population 
with a dysfunctional FFA4 variant has an increased risk of obesity supported a significant role of 
the receptor in metabolic diseases.11 Further support for this was recently provided by the finding 
that the selective FFA4 agonist Cpd A (Chart 1) increased insulin sensitivity and reduced 
inflammation and hepatic steatosis in mice fed a high-fat diet.12 Moreover, FFA4 is implicated in 
regulation of glucagon, ghrelin and somatostatin release (or secretion), representing likely 
contributing mechanisms of the observed metabolic phenotype.13-16  
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Chart 1. Representative FFA4 agonists 
Although unsaturated and, in particular, omega-3 fatty acids were highlighted in the initial 
publications,8,10 it has become clear that FFA4 is activated by long-chain fatty acids with a 
profile that overlaps extensively with those that activate the more established antidiabetic target 
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free fatty acid receptor 1 (FFA1/GPR40).17 In 2012, we disclosed TUG-891 (1, Chart 1) as the 
first potent and selective FFA4 agonist, optimized from a series of FFA1 agonists originally 
derived from fatty acids.18,19 However, the significantly higher potency of 1 at the murine (m) 
FFA1 resulted in a selectivity of 70-fold in a β-arrestin-2-based assay and of only 3-fold in a 
calcium assay for mFFA4 over mFFA1, essentially rendering the compound a dual agonist in 
mice, at least with respect to signals and functions mediated by the induced elevation of Ca2+.20  
In 2008, a patent from Banyu disclosed a series of non-acidic benzosultams as FFA4 agonists 
structurally distinct from other known FFA4 agonists.21 The structures were also markedly 
different from known FFA1 ligands and appeared to represent an opportunity to access FFA4 
agonists with complete selectivity over FFA1. More recently, Sparks and co-workers reported a 
series of sulfonamide FFA4 agonists with GSK1237647A (2, Chart 1) as the preferred compound 
with pEC50 = 6.3 and a lack of activity on FFA1. However, this compound was also described as 
unsuitable for in vivo studies due to poor solubility.22 Herein, we report structure-activity 
relationship studies around these compound series, leading to the identification of a full FFA4 
agonist with complete selectivity over FFA1. We further demonstrate activity in vivo and report 
beneficial results on glucose regulation, insulin sensitivity and bodyweight of the selected 
compound in DIO mice.  
SYNTHESIS 
The initial compounds were synthesized by nucleophilic aromatic substitution at 1,3-difluoro-
5-nitrobenzene, reduction of 3a-c to anilines 4a-c, formation of the sulfonamides 5a-c, reduction 
(6a-c) and cyclization to provide sultams 7-9, essentially following the synthetic strategy 
described in Banyu’s patent (Scheme 1).21 Aniline 4a was also substrate for the synthesis of 
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phthalimide 12 and for the acyclic sulfonamides 13 and 14. Acyclic sulfonamides, including 15-
19, were synthesized similarly from the corresponding sulfonyl chlorides and anilines. 
Scheme 1. Synthesis of compounds using a previously described routea,21 
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aReagents and conditions: (a) K2CO3, DMF, 100 
oC, 16 h (30-68%). (b) Y = O: NH4HCO2, 
Pd/C, EtOH, 90 oC (µν), 10 min (quant.); Y = CH2O: SnCl2, MeCN/EtOH (1:1), refl., 1 h (86%). 
(c) Pyridine, rt, 16 h (50-96%). (d) LiAlH4, THF, 0 
oC, 0.5–2 h (48-95%); e) PBr3, THF, 0 
oC to 
rt, 0.5 h; Na2CO3 (sat. aq.), 1 h (44-83%). (f ) phtalic anhydride, acetic acid, 100 
oC, 16 h (68%); 
(g) MeI, NaH, DMF, 0 oC to rt, 1 h (65-78%). 
Since this synthetic route to the sultam is cumbersome and unsuitable for variations in the 
eastern part of the structure, a more straightforward coupling procedure was developed. Thus, the 
benzosultam intermediate 20, obtained from saccharin, was subject to copper(I)-catalyzed cross-
coupling with 4-iodophenol followed by Ullmann coupling to give 22, with 1-bromo-3-
phenoxybenzene to give 23, and with 3-bromo-5-fluorophenol to give the central intermediate 25 
(Scheme 2). Further Ullmann condensation of 25 with aryl bromides or iodides provided the 
target compounds (26-34). The monocyclic 24 was synthesized from 3-phenoxyaniline and 3-
chloropropanesulfonyl chloride (Scheme 3). Analogues with the central fluoro substituent 
removed (36) or replaced by chloro (38) were synthesized by nucleophilic aromatic substitution 
of 2-fluoropyridine with the respective halophenols followed by copper(I)-catalyzed cross-
coupling with 20 (Scheme 4). 
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Scheme 2. Synthesis of N-arylbenzosultams from saccharina 
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aReagents and conditions: a) LiAlH4, THF, 0 
oC to rt, 16 h (78%). (b) 4-Iodophenol or 3-
bromo-5-fluorophenol, CuI, DMEDA, K2CO3, MeCN, 70 
oC, 16 h (65-96%). (c) Aryl halide (Br 
or I), picolinic acid, CuI, K3PO4, DMSO, 90 
oC (12-83%), 24 h.  
Scheme 3. Synthesis of sultam 24a 
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24  
aReagents and conditions: a) 3-Chloropropanesulfonyl chloride, pyridine, CH2Cl2, rt, 16 h. b) 
K2CO3, DMF, 50 °C, 16 h (72% over two steps). 
Scheme 4. Synthesis of non-fluorinated analoguesa 
 
aReagents and conditions: (a) K2CO3, DMF, 140 
oC (µν), 4-5½ h (62-65%). b) 20, CuI, 
DMEDA, K2CO3, MeCN, 70 
oC, 16 h (61-88%). 
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RESULTS AND DISCUSSION 
The compounds were screened on human FFA4 in a β-arrestin-2 recruitment assay and 
compounds of particular interest were further tested in a Ca2+ mobilization assay and on human 
FFA1.18 The sultam 7, disclosed as an FFA4 agonist with pEC50 of 6.74 in the Banyu patent,
21 
showed somewhat lower activity in our assays with a pEC50 of 6.36 in the β-arrestin-2 assay and 
6.52 in the calcium assay (Table 1). Notably, the compound did not show any activity on FFA1 
at concentrations up to 100 µM. (possibly move the following sentence to here as this compound 
is also noted in the Legend to Table 1 as well as in Supplemental) The FFA1 agonist 1023 was 
found to also act as a full FFA4 agonist,18  and has been used as a reference compound (see the 
Supporting Information). 
 
Table 1. Initial exploration of the pyridine ring of 7. 
N
S
O O
F
O
R
 
 
a BRET-based β-arrestin recruitment based FFA4 assay. Efficacy (Emax) is relative to 100 µM 10 
(3-(4-(o-tolylethynyl)phenyl)propanoic acid, TUG-424).23 bCa2+ FFA4 assay. Efficacy (Emax) is 
Code R hFFA4  hFFA1 
  β-Arr. pEC50 
(Emax)
a 
Ca2+ pEC50 (Emax)
b Ca2+ pIC50  
(Imax)
c 
7 
N
O
 
6.36 ± 0.05 (107) 6.52 ± 0.09 (115) < 4 
8 O
 
6.63 ± 0.18 (101) 6.42 ± 0.13 (78) 5.41 ± 0.01 (47) 
9 
O
 
<4 –d 5.61 ± 0.63 (36) 
 8 
relative to 100 µM 10. cTested in the FFA1 Ca2+ assay as agonists and antagonists. Imax denotes 
% reduction of the response of 300 nM 10. All compounds were inactive as FFA1 agonists. dNot 
tested. 
 
Studies with 7 on FFA4 mutants directed at the orthosteric binding site revealed that the 
activity depends critically on Arg992.64, the residue identified as the key anchoring point for the 
carboxylate group of free fatty acids and orthosteric ligands such as 1.24 This observation was 
initially surprising in light of the distinctly different structure and the lack of any acidic group. 
Compound 7 was also affected by other mutations that impact the activity of 1 and α-linolenic 
acid, strongly suggesting that 7 also binds to the orthosteric site (Table S1).24 Thus, mutations 
that eliminate or significantly reduce the activity of α-linolenic acid and 1 (W104A, F1153.29A, 
W2075.38A, F2115.42A, W2776.48A and F3047.36A eliminate activity of both, F882.53A, I2845.66A, 
F3037.35H and T3107.42A significantly reduce activity of both α-linolenic acid and 1, T1193.33A, 
I1263.40A, N2155.46A, I2806.51A, I2816.52F only reduce the activity of 1, see Table S1) also affect 
the activity of 7 in a similar manner. Exceptions were W1002.65A and L1143.28A, which affected 
1 but not 7, as well as V2125.43A, and F3117.43A, which each significantly decreased potency of 
7, while only producing smaller non-significant decreases in the potency of 1. Computational 
modeling indicated favored alternative docking poses in the orthosteric site of FFA4 with 7 
directly interacting with Arg992.64 by hydrogen bonds either to the sultam oxygen atoms or to the 
pyridyl nitrogen. To investigate the most likely orientation, the phenyl analogue 8, lacking the 
pyridyl interaction possibility, was synthesized and found more potent on FFA4 than 7, 
indicating the sulfonamide as the Arg992.64 interaction point (Figure 1). (And if this is moved to 
above Table 1 can be removed from here) The FFA1 agonist 1023 was found to also act as a full 
FFA4 agonist,18  and has been used as a reference compound (see the Supporting Information). 
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Figure 1. Docking pose for 7 in FFA4. Residues where mutation significantly affects the 
functional activity of 7 have been displayed. 
To probe the importance of the sulfonamide, phthalimide 12, also exemplified in the Banyu 
patent but without activity data,21 was produced and found to have 10-fold lower activity than 7 
and low partial efficacy, indicating that the sulfonamide is important for agonist activity but that 
replacement by other hydrogen bond acceptors is possible. The acyclic sulfonamide 13, 
containing a weakly acidic group (calculated pKa 7.7)
25 exhibited further reduced activity. 
Interestingly, N-methylation to give the non-acidic ring-opened analogue 14 resulted in complete 
loss of activity, possibly reflecting that planarity between the aromatic ring and the S-N bond is a 
requirement.  
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Table 2. Lead structures and western part variations. 
Code Structure hFFA4  hFFA1 
  
BRET pEC50 
(Emax)
a 
Ca2+ pEC50 (Emax)
b 
 Ca2+ pIC50  
(Imax)
c 
12 
F
O
N
N
O
O
  
5.30 ± 0.08 (45) –d  –d 
13 
O
N
H
N
S
O O
F
F  
4.78 ± 0.15 (39) –d   nre 
14 
O
N
N
S
O O
F
F  
 nre –d   nre 
15  
H
N
S
F
OO  
5.27 ± 0.36 (76)  nrh  5.09 ± 0.15 (68) 
16  
H
N
S
F
OO
O  
5.45 ± 0.01 (52)  nrh  4.89 ± 0.10 (95) 
17  NS
F
OO
O  
 nre –d  4.97 ± 0.15 (57) 
2  (Chart 1) 6.31 ± 0.09 (82) –d   nre 
18 
H
N
S
MeO
OO
O  
 nre –d   nre 
19 
H
N
S
Me
OO
O  
 nre  nre  5.00 ± 0.09 (100) 
22 S N
O O
O  
 nre –d   nre 
23 S N
O O
O
 
6.61 ± 0.07 (95) 6.68 ± 0.06 (105)  6.76 ± 1.34 (39) 
24 S N
O O
O
 
 nre  nre   nre,f 
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aBRET-based β-arrestin recruitment based FFA4 assay. Efficacy (Emax) is relative to 10. bCa2+ 
FFA4 assay. Efficacy (Emax) is relative to 10. 
cTested in the FFA1 Ca2+ assay as agonists and 
antagonists. All compounds were inactive as FFA1 agonists. Imax denotes % reduction of the 
response of 300 nM 10. dNot tested. eNo response up to 100 µM. fTested as antagonist in the 
FFA1 Ca2+ mobilization assay with 20 nM TUG-770 (11).26  
Related to 13, the sulfonamide DC260126 (15) has been described as an FFA1 antagonist and 
was, somewhat surprisingly, reported to improve insulin sensitivity and β-cell function in rats 
and db/db mice.27,28 We confirmed its FFA1 antagonist activity (pIC50 = 5.09) but found that the 
compound also acts as an FFA4 agonist in the β-arrestin-2 recruitment assay although it was 
devoid of activity in the Ca2+ assay (Table 2), and thus represents a relatively low-potency, but 
completely β-arrestin-biased, FFA4 agonist. Since FFA4 is proposed to mediate anti-
inflammatory effects via the β-arrestin pathway, it cannot be excluded that the tendency to 
insulin sensitization observed with this compound is mediated by FFA4.  
Replacement of the butyl of 15 by phenoxy (16) gave a compound with similar FFA1 
antagonist and FFA4 agonist properties. N-methylation of the potentially acidic sulfonamide (17) 
led to loss of FFA4 activity but preserved FFA1 antagonism. The related sulfonamide 2 (Chart 1) 
was recently reported as a selective FFA4 agonist.22 We confirmed a pEC50 of 6.31 in the β-
arrestin-2 assay. Replacement of the para-fluoro of 16 with methoxy (18) akin to 2 resulted in 
complete loss of activity, as did para-phenoxyphenyl sultam 22, whereas the moderate FFA1-
antagonistic activity was maintained with a para-methyl substituent (19). Interestingly, removing 
the meta-fluoro of the phenyl analogue 8 resulted in a compound (23) with preserved potency in 
both the β-arrestin-2 and calcium assay on FFA4 as well as preserved partial antagonist activity 
on FFA1. In contrast, removing the benzene ring fused to the sultam (24) resulted in a compound 
devoid of activity on both FFA4 and FFA1, indicating a critical role of this ring. 
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Explorations of the western part of the structure indicated that the benzosultam system was 
favored. Turning attention back to the eastern site, the eastern phenyl ring of 8 was scanned with 
the non-polar methyl substituent (26, 27, 28) and the polar cyano (29-31) and meta-cyanomethyl 
(32) substituents, in all cases these resulted in decreased potency with para-substituents being 
somewhat better tolerated (Table 3).  
Table 3. Exploration of the central and eastern parts.  
N
S
O O
R
X  
Code R X hFFA4  hFFA1 
   β-Arr. pEC50 
(Emax)
a 
Ca2+ pEC50 (Emax)
b  
Ca2+ pIC50 
 (Imax)
c 
26 
O
 
F 5.57 ± 0.10 (42)  nrd  4.35 ± 0.23 (71) 
27 
O
 
F 5.58 ± 0.24 (87) 5.35 ± 0.17 (14)  4.60 ± 0.16 (51) 
28 
O
 
F 6.36 ± 0.09 (91) 5.96 ± 0.20 (38)  5.54 ± 0.12 (52) 
29 O
CN
 
F 4.79 ± 0.27 (76) –e  <4 
30 
O CN
 
F 5.24 ± 0.22 (83) –e  5.47 ± 0.94 (52) 
31 
O
CN
 
F 5.78 ± 0.09 (87) 5.63 ± 0.16 (29)  6.21 ± 0.66 (43) 
32 
O
CN
 
F 5.28 ± 0.10 (57) –e  4.70 ± 0.08 (44) 
33 N
O
 
F 5.90 ± 0.05 (97) 5.77 ± 0.16 (120)  <4 
 13 
34 N
O
 
F 6.91 ± 0.04 (98) 6.63 ± 0.13 (130)  <4 
36 N
O
 
H 5.81 ± 0.11 (102) 5.99 ± 0.19 (93)  <4 
38 N
O
 
Cl 6.86 ± 0.10 (113) 7.41 ± 0.18 (78)  <4f 
aBRET-based β-arrestin-2 recruitment based FFA4 assay. Efficacy (Emax) is relative to 100 µM 
10. bCa2+ FFA4 assay. Efficacy (Emax) is relative to 100 µM 10. cTested in the FFA1 Ca2+ assay 
as agonists and antagonists. All compounds were inactive as FFA1 agonists. Imax denotes % 
reduction of the response of 300 nM 10. dNo response up to 100 µM. eNot tested. fTested as 
antagonist in the FFA1 Ca2+ mobilization assay with 20 nM TUG-770 (11).26  
 
Further investigation of 8 revealed antagonistic activity on FFA1, but without the ability to 
completely block the agonist response (i.e. “partial antagonism”, Table 1). A similar effect was 
seen with all substituted analogues exhibiting noticeable agonistic activity (EC50 <10 µM) on 
FFA4. These results are surprising because they indicate that this compound series also has the 
ability to interact with and modulate FFA1 despite its structural dissimilarity from other FFA1 
agonists and the absence of an acidic functional group. However, the inability of the compounds 
to completely block activity of 10 suggests non-competitive binding and allosteric interaction 
with FFA1. 
In contrast to the phenoxy compounds, the pyridines 7, 33, 13, 14 did not show any sign of 
agonistic or antagonistic activity on FFA1. These structures were therefore explored further by 
altering the attachment point at the pyridine. Thus, the 4-pyridyl (33) derivative resulted in a 3-
fold reduced potency, whereas the 2-pyridyl (34) gratifyingly showed a 3.5-fold increased 
potency to achieve an EC50 of 128 nM. 
Finally, the importance of the meta-fluoro substituent at the central ring of 34 was assessed. 
Removal of the fluoro substituent in 36 resulted in a 10-fold reduced potency and indicated that, 
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contrary to 8, the meta-fluoro contributes to the potency of 34. In contrast, substitution of fluoro 
by chloro in 38 led to preserved activity in the β-arrestin-2 recruitment assay and an EC50 of 40 
nM in the Ca2+ assay, a 6-fold increase in potency relative to 34, albeit with reduced efficacy.  
Overall, 34 and 38 stood out at the most potent FFA4 agonists in both the β-arrestin-2 and the 
Ca2+ assays with essentially equal activity in the former. Although 38 appeared more potent in 
the Ca2+ assay, the compound showed only partial agonist activity, whereas 34 was a full agonist 
in both assays as well as less lipophilic (∆ClogP ~0.5). Compound 34 showed no activity at the 
other free fatty acid receptors FFA1, FFA2 or FFA3 at up to 30 µM concentration, indicating 
>300-fold selectivity. Experimental log D7.4 measurements showed identical lipophilicity for 34 
and 7 (3.17 and 3.12, respectively). Solubility studies for compounds 7, 34 and 38 in PBS 
indicated progressively lower solubility with 38 being virtually insoluble (11, 1.3 and 0.1 µM, 
respectively), however, the solubility of the two latter in FaSSIF (what is this?) gave a somewhat 
better picture for 34 (14 µM for 34 and 0.9 µM for 38). Thus, 34 was selected for in vivo studies. 
The low solubility of the compound did not cause any problems in relation to these. Prior to the 
mouse studies, the activity and specificity of 34 and the two other most potent and selective 
agonists, 7 and 38, on the murine receptor orthologues were investigated. Completely preserved 
activity was confirmed for all three compounds in the Gq-dependent calcium mobilization assay 
on mFFA4 (pEC50 = 7.08 ± 0.05, 6.83 ± 0.08 and 7.14 ± 0.08 for 7, 34 and 38, respectively), 
with no activity detected up to 100 µM concentration on mFFA1. Further, 34 was also tested in 
the β-arrestin assay, confirming full agonistic activity with pEC50 = 6.32 ± 0.06, again with no 
sign of any activity on mFFA1. Compound 34 also failed to induce a response when tested on the 
FFA4 R992.64Q mutant, supporting the notion that this compound binds as indicated for 7 in 
Figure 1. 
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FFA4 has been reported to mediate free fatty acid promoted incretin release and to improve 
glucose tolerance,8,12 and mice lacking FFA4 show impaired glucose homeostasis, an effect 
believed to involve improper regulation of glucagon secretion.14 Thus, the effect of 34 as well as 
7 in a glucose tolerance test was investigated by oral dosing prior to an oral glucose challenge. 
This resulted in significant lowering of plasma glucose levels for both compounds compared to 
vehicle (Figure 2).  
 
Figure 2. FFA4 agonists 34 and 7 lower plasma glucose concentrations compared to vehicle 
after oral dosing at 10 mg/kg 15 min before oral glucose challenge (n = 6 mice per group, 
*p=<0.5; **p=<0.01, two-way ANOVA with Bonferoni post hoc test). 
FFA4 has attracted high interest as a potential antidiabetic target in particular because of 
results indicating that the receptor mediates insulin sensitization, anti-inflammatory effects, 
protection of pancreatic islets, and that it may even counteract obesity.3-6,10,11,29 However, each of 
these is difficult to assess satisfactorily in acute treatment studies. To evaluate the effects of 34 
on some of these, a chronic treatment study in DIO mice was performed with daily dosing of 10 
mg/kg 34 over a three week period. Mice lacking FFA4 were included to assess and confirm 
receptor specific activity of the ligand. The wild-type mice were littermates of the FFA4(-/-) 
animals. As observed in normal mice, a glucose challenge 15 min after dosing in DIO mice on 
the first day significantly reduced plasma glucose levels in 34-treated wild-type mice compared 
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to vehicle-treated wild-type mice, whereas 34 had no effect on glucose levels in the FFA4(-/-) 
animals (Figure 3). The effect was significant in the wild-type animals also when calculated 
relative to t = -30 min or t = 0 (see the Supporting Information). This confirms that the effect of 
34 on glucose excursion when dosed 15 minutes before the challenge is mediated by FFA4. 
Studies to investigate the mechanism of this effect are in progress. 
 
Figure 3. Acute oral glucose tolerance test on day 0 (n=9 mice per group; *p=<0.05, **p=<0.01, 
***p<0.005, two-way ANOVA with Bonferroni post hoc test) performed on DIO mice. (Maybe 
this is a test but apart from the scale bar for the time axis I can’t see differecnes between the 
upper and lower versions of these Figures apart from a change in the measured statistical 
significance?) 
After treatment over 21 days, the fasting insulin levels of the 34 treated wild-type (unclear if 
this is DIO or not animals) mice was significantly reduced compared to vehicle treated mice, 
whereas no difference was observed between the FFA4(-/-) groups (Figure 4, top). These results 
indicate that 34 promotes insulin sensitization in mice through activation of FFA4. An oral 
glucose tolerance test on day 21 (Figure 4, bottom) showed an even more robust effect than on 
day 0, presumably an effect of increased insulin sensitization.  
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Figure 4. Fasting insulin levels after chronic dosing with 34 for 21 days (top) and oral glucose 
tolerance test at day 21 (bottom) (n=9, **p=<0.01, **** p=<0.001, one-way ANOVA with 
Dunnett’s post hoc test).  
Previous studies have linked FFA4 to obesity by demonstrating a correlation between 
expression and obesity and have indicated an increased risk of obesity with p.R270H FFA4 
variant in European populations or with deletion of the receptor in mouse,5,11 although a recent 
study failed to find a similar association in a Danish population.30 No significant effect was 
observed on either food or water intake over the course of the treatment for 21 days in either the 
wild-type or FFA4(-/-) animals, although a weak tendency towards reduced food intake for the 
34 treated wild-type group was observed (see the Supporting Information). Treatment with 34 
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did, however, result in a reduction in bodyweight in the wild-type mice of 3-4 grams (7-9%) 
towards the end of the study, whereas no effect, or even a weak trend towards weight gain, was 
observed in the FFA4(-/-) animals (Figure 5). These results support the notion that FFA4 may 
represent a potential anti-obesity target, an effect that would be an important add-on to regulation 
of glucose homeostasis in an antidiabetic drug. 
 
Figure 5. Bodyweight change in DIO wild-type and FFA4(-/-) mice over 21 days of once daily 
dosing (10 mg/kg, po) with 34 (n=9 mice per group, *p=<0.5; ***p=<0.001; two-way ANOVA 
with Bonferroni post hoc test). 
 
CONCLUSION 
Most currently known FFA4 agonists are carboxylic acids assumed to mimic the endogenous 
free fatty acid agonists. Most of these also exhibit some degree of activity on FFA1. In the search 
for highly selective FFA4 agonists, we investigated a non-acidic benzosultam ligand known from 
the patent literature and conducted a preliminary structure-activity relationship study around this 
scaffold. Interestingly, mutagenesis studies indicated that these compounds also bind to the same 
site as α-linolenic acid and 1 and also require carboxylate interaction partner Arg992.64 for 
activity despite the absence of a carboxylate. Given the limited overall homology between FFA1 
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and FFA4, even though they are both activated by overlapping sets of medium- and longer-chain 
free fatty acids, it was surprising that a sub-series of these compounds also interacted with FFA1 
to produce partial blockade of this receptor. Compound 34, a full FFA4 agonist showed 
comparable potency in both Ca2+- and β-arrestin-2-based assays with complete selectivity over 
FFA1 and other free fatty acid receptors. Its distinctly different structure from the carboxylic 
acid FFA4 agonists currently used as tool compounds makes 34 a suitable orthogonal tool in 
combination with these for further studies of the function of FFA4. The compound was 
investigated in vivo and was found to lower plasma glucose levels after an oral glucose challenge 
when dosed orally 15 minutes prior to the challenge, an effect that was confirmed to be mediated 
by FFA4 as this was not observed in animals lacking FFA4. Furthermore, 34 robustly increased 
insulin sensitivity after chronic dosing in DIO mice and led to moderately reduced bodyweight 
over the course of the study, despite no significant effects on food or water intake. Altogether, 34 
is a non-acidic full agonist of FFA4 with complete selectivity over FFA1 that shows antidiabetic 
and anti-obesity effects after chronic oral dosing in DIO mice, corroborating FFA4 as a 
promising new antidiabetic target.  
 
EXPERIMENTAL SECTION 
Synthesis 
Commercial starting materials and solvents were used without further purification. THF was 
freshly distilled from sodium/benzophenone. Water was filtered and demineralized (Milli-Q). 
TLC was performed on TLC Silica gel 60 F254 plates and visualized at 254 nm and/or by 
staining with phosphomolybdic acid, vanillin, or KMnO4 stains. Petroleum ether (PE) refers to 
alkanes with bp 60-80 oC. Microwave reactions were performed in a Biotage Initiator+ 
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microwave reactor. Purification by flash chromatography was carried out using silica gel 60 
(0.040-0.063 mm, Merck). 1H, 13C and 19F NMR spectra were recorded at 400, 101, and 376 
MHz respectively on Bruker Avance III 400 at 300 K. High-resolution mass spectra (HRMS) 
were obtained on a Bruker micrOTOF-Q II (ESI). Purity was determined by HPLC and 
confirmed by inspection of NMR spectra (1H, 13C, 19F NMR). HPLC analysis was performed 
using a Dionex 120 C18 or a Gemini C18 column (5 µm, 4.6x150 mm); flow: 1 mL/min; 10% 
MeCN in water (0-1 min), 10-100% MeCN in water (1-10 min), 100% MeCN (11-15 min), with 
both solvents containing 0.05% TFA or 0.1% HCOOH as modifier; UV detection at 254 nm. All 
test compounds were of e95% purity unless otherwise stated.  
2-(4-Hydroxyphenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (21). To 20 (250 mg, 1.48 
mmol), CuI (42 mg, 0.22 mmol), 4-iodophenol (390 mg, 1.77 mmol) and anhydrous K2CO3 (615 
mg, 4.45 mmol) under argon were added dry and freshly degassed acetonitrile (5 mL) and 
DMEDA (80 µL, 0.75 mmol). The reaction mixture was heated at 70 ºC for 16 h. The reaction 
was then quenched with aqueous HCl (2N, 10 mL) and the aqueous phase was extracted with 
EtOAc (3x). The combined organic phases were dried (Na2SO4) and concentrated. The crude 
product was purified by flash chromatography (EtOAc/PE, 1:1) and the product obtained 
recrystallized from EtOAc/PE (1:1) to give 21 as a yellow solid (232 mg, 65%). 1H NMR (400 
MHz, acetone-d6): 8.51 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.78 (t, J = 7.6 Hz, 2H), 7.69 (t, J = 7.6 
Hz, 2H), 7.41 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 4.93 (s, 2H). 13C NMR (100 MHz, 
acetone-d6): 156.8, 136.4, 134.5, 133.7, 130.2, 129.5, 125.94, 125.93, 121.8, 116.9, 51.9. HRMS 
(ESI) calcd for C13H11NNaO3S [M+Na]
+ 284.0352, found 284.0347. HPLC tR = 9.4 min, 99.6%. 
2-(4-Phenoxyphenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (22). To 21 (75 mg, 0.29 
mmol), 4-iodobenzene (48 µL, 0.43 mmol), copper iodide (11 mg, 0.06 mmol), picolinic acid 
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(14.8 mg, 0.12 mmol) and K3PO4 (123 mg, 0.58 mmol) under argon was added dry DMSO (0.5 
mL) and the reaction mixture was heated at 90 ºC for 24 h. The temperature was then allowed to 
reach rt and the reaction mixture was partitioned between water and EtOAc. The aqueous phase 
extracted with EtOAc (2x) and the combined organic phases were washed with brine, dried 
(Na2SO4) and concentrated. The crude product was purified by flash chromatography 
(EtOAc/PE, 3:7) and recrystallized from EtOAc/PE (2:1) to give 22 as light yellow solid (80 mg, 
83%). 1H NMR (400 MHz, CDCl3): 7.88 (d, J = 7.6 Hz, 1H), 7.66 (td, J = 7.6, 0.9 Hz, 1H), 7.59 
(t, J = 7.6 Hz, 1H), 7.49 – 7.44 (m, 3H), 7.35 (t, J = 8.0 Hz, 2H), 7.12 (t, J = 7.4 Hz, 1H), 7.12 
(d, J = 8.9 Hz, 2H), 7.12 (d, J = 7.7 Hz, 2H), 4.84 (s, 2H). 13C NMR (100 MHz, CDCl3): 157.1, 
155.2, 135.0, 133.0, 132.5, 131.6, 129.9, 129.5, 124.4, 123.5, 123.5, 121.6, 120.0, 118.9, 50.8. 
HRMS (ESI) calcd for C19H15NNaO3S [M+Na]
+ 360.0665, found 360.0653. HPLC tR = 12.3 
min, 99.7%. 
2-(3-Phenoxyphenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (23). The title compound 
was obtained as described for 21 using 20 (100 mg, 0.59 mmol) and 3-bromodiphenylether (129 
µL, 0.71 mmol) as starting materials. The crude product was purified by flash chromatography 
(EtOAc/PE, 3:7) and the product recrystallized from EtOAc/PE (2:1) to give 23 as a white solid 
(175 mg, 88%). 1H NMR (400 MHz, CDCl3): 7.86 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 
7.58 (t, J = 7.6 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.39 – 7.31 (m, 3H), 7.27 (dd, J = 8.2, 1.3 Hz, 
1H), 7.13 (t, J = 7.4 Hz, 1H), 7.09 – 7.02 (m, 3H), 6.78 (dd, J = 8.2, 1.3 Hz, 1H), 4.82 (s, 2H). 
13C NMR (100 MHz, CDCl3): 158.5, 156.7, 138.5, 135.0, 133.2, 131.9, 130.7, 129.9, 129.5, 
124.5, 123.7, 121.6, 119.2, 114.3, 113.5, 109.4, 49.5. HRMS (ESI) calcd for C19H15NNaO3S 
[M+Na]+ 360.0665, found 360.0655. HPLC tR = 12.3 min, >99.9%. 
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2-(3-Phenoxyphenyl)isothiazolidine 1,1-dioxide (24). Step 1: To a solution of 3-
phenoxyaniline (501 mg, 2.71 mmol) in dry CH2Cl2 (10 mL) was added pyridine (0.57 mL, 7.02 
mmol) and 3-chloropropanesulfonyl chloride (0.4 mL, 3.24 mmol) at room temperature. The 
reaction was stirred for 16 h, then diluted with CH2Cl2 and washed successively with 1N HCl 
(aq) and sat. NaHCO3 (sat. aq.), dried (Na2SO4) and concentrated to give 3-chloro-N-(3-
phenoxyphenyl)propane-1-sulfonamide as a crude yellow oil that was used directly in the next 
step. Step 2: To a solution of 3-chloro-N-(3-phenoxyphenyl)propane-1-sulfonamide in DMF (15 
mL) was added K2CO3 (963 mg, 6.97 mmol) and stirred at 50 °C for 16 h. The reaction mixture 
was cooled to room temperature, diluted with water and extracted three times with EtOAc (3x). 
The combined organic phases were washed with water and brine, dried (Na2SO4) and 
concentrated. The crude was purified by flash chromatography (EtOAc:PE, 1:1) to give 24 as a 
pale yellow oil which solidified to an off-white solid after a week under high vacuum (596 mg, 
72% over two steps): 1H NMR (400 MHz, CDCl3) ´  7.37 – 7.27 (m, 3H), 7.14 – 7.00 (m, 4H), 
6.88 (t, J = 2.2 Hz, 1H), 6.74 (dd, J = 8.2, 2.2 Hz, 1H), 3.74 (t, J = 6.5 Hz, 2H), 3.37 (t, J = 7.5 
Hz, 2H), 2.52 (p, J = 7.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) ´  158.2, 156.9, 139.3, 130.5, 
129.9, 123.7, 119.2, 114.3, 113.9, 109.7, 48.5, 46.8, 18.8; HRMS (ESI) m/z: calculated 
C15H15NNaO3S [M+Na
+] = 312.0665, found 312.0663.HPLC: tR = 11.62 min, 99.5%. 
2-(3-Fluoro-5-hydroxyphenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (25). The title 
compound was obtained as described for 21 using 20 (500 mg, 3 mmol) and 3-bromo-5-
fluorophenol (677 mg, 3.55 mmol) as starting materials. The crude product was purified by flash 
chromatography (EtOAc/PE, 1:1) to give the desired compound 25 as a white solid (793 mg, 
96%). 1H NMR (400 MHz, DMSO-d6): 10.23 (broad s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.82 (dt, J 
= 7.6, 1.0 Hz, 1H), 7.71 – 7.67 (m, 2H), 6.80 (t, J = 1.9 Hz, 1H), 6.67 (dt, J = 11.1, 2.2 Hz, 1H), 
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6.39 (dt, J = 10.7, 2.2 Hz, 1H), 5.04 (s, 2H). 13C NMR (100 MHz, DMSO-d6): 163.4 (d, J = 
240.6 Hz), 159.6 (d, J = 14.1 Hz), 139.2 (d, J = 13.9 Hz), 133.9, 133.7, 132.2, 129.6, 125.2, 
121.0, 101.0 (d, J = 2.4 Hz), 98.0 (d, J = 23.8 Hz), 95.9 (d, J = 26.8 Hz). 49.0. HRMS (ESI) 
calcd for C13H10FNNaO3S [M+Na]
+ 302.0258, found 302.0256. HPLC tR = 10.3 min, 99.2%. 
The spectra is in accordance with the literature.21 
2-(3-Fluoro-5-(o-tolyloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (26). The 
title compound was obtained as described for 22 using 25 (70 mg, 0.25 mmol) and 2-
bromotoluene (45 µL, 0.38 mmol) as starting materials. The crude product was purified by flash 
chromatography (EtOAc/PE, 1:4) and recrystallized from EtOAc/PE (3:1) to give 26 as a white 
solid (23 mg, 25%). 1H NMR (400 MHz, CDCl3): 7.86 (d, J = 7.6 Hz, 1H), 7.68 (t, J = 7.6 Hz, 
1H), 7.59 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 
Hz, 1H), 7.14 (t, J = 7.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.93 (dt, J = 10.3, 1.9 Hz, 1H), 6.81 
(s, 1H), 6.29 (dt, J = 10.0, 1.9 Hz, 1H), 4.80 (s, 2H), 2.22 (s, 3H). 13C NMR (100 MHz, CDCl3): 
164.1 (d, J = 245.6 Hz), 160.3 (d, J = 12.8 Hz), 153.1, 139.3 (d, J = 13.2 Hz), 134.8, 133.4, 
131.8, 131.5, 130.4, 129.6, 127.5, 125.2, 124.5, 121.6, 120.6, 102.5 (d, J = 2.9 Hz), 99.6 (d, J = 
25.5 Hz), 99.5 (d, J = 26.9 Hz), 49.3, 16.1. HRMS (ESI) calcd for C20H16FNNaO3S [M+Na]
+ 
392.0727, found 392.0715. HPLC tR = 12.2 min, 99.2%. 
2-(3-Fluoro-5-(m-tolyloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (27). The 
title compound was obtained as described for 22 using 25 (70 mg, 0.25 mmol) and 3-iodotoluene 
(48 µL, 0.38 mmol) as starting materials. The crude product was purified by flash 
chromatography (EtOAc/PE, 3:7) and recrystallized from EtOAc/PE (3:1) to give 27 as a white 
solid (33 mg, 36%). 1H NMR (400 MHz, CDCl3): 7.86 (d, J = 7.7 Hz, 1H), 7.68 (t, J = 7.7 Hz, 
1H), 7.59 (t, J = 7.7 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.01 – 6.94 (m, 
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2H), 6.90 – 6.82 (m, 3H), 6.42 (dt, J = 9.8, 2.0 Hz, 1H), 4.80 (s, 2H), 2.36 (s, 3H). 13C NMR (100 
MHz, CDCl3): 164.0 (d, J = 245.8 Hz), 160.0 (d, J = 12.8 Hz), 155.7, 140.3, 139.3 (d, J = 13.1 
Hz), 134.8, 133.4, 131.5, 129.7, 129.6, 125.3, 124.5, 121.6, 120.4, 116.8, 103.8 (d, J = 2.9 Hz), 
101.0 (d, J = 25.1 Hz), 100.0 (d, J = 26.9 Hz), 49.3, 21.4. HRMS (ESI) calcd for 
C20H16FNNaO3S [M+Na]
+ 392.0727, found 392.0716. HPLC tR = 13.1 min, 99.4%. 
2-(3-Fluoro-5-(p-tolyloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (28). The 
title compound was obtained as described for 22 using 25 (70 mg, 0.25 mmol) and 4-iodotoluene 
(82 mg, 0.38 mmol) as starting materials. The crude product was purified by flash 
chromatography (EtOAc/PE, 3:7) and recrystallized from EtOAc/PE (3:1) to give 28 as a white 
solid (24 mg, 26%). 1H NMR (400 MHz, CDCl3): 7.87 (d, J = 7.7 Hz, 1H), 7.68 (td, J = 7.7, 0.8 
Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.19 (d, J = 8.2 Hz, 2H), 7.00 – 6.92 
(m, 3H), 6.84 (s, 1H), 6.41 (dt, J = 9.9, 2.0 Hz, 1H), 4.80 (s, 2H), 2.36 (s, 3H). 13C NMR (100 
MHz, CDCl3): 164.0 (d, J = 245.7 Hz), 160.4 (d, J = 12.6 Hz), 153.2, 139.3 (d, J = 13.2 Hz), 
134.8, 134.2, 133.4, 131.5, 130.5, 129.6, 124.5, 121.6, 119.9, 103.4 (d, J = 3.0 Hz), 100.7 (d, J = 
25.3 Hz), 99.9 (d, J = 27.0 Hz), 49.3, 20.8. HRMS (ESI) calcd for C20H16FNNaO3S [M+Na]
+ 
392.0727, found 392.0714. HPLC tR = 13.1 min, 99.7%. 
2-(3-(1,1-Dioxidobenzo[d]isothiazol-2(3H)-yl)-5-fluorophenoxy)benzonitrile (29). The title 
compound was obtained as described for 22 using 25 (79 mg, 0.28 mmol) and 2-
bromobenzonitrile (40 mg, 0.22 mmol) as starting materials. The crude product was purified by 
flash chromatography (EtOAc/PE, 1:4) and the title compound 29 was recrystallized from 
EtOAc/PE (3:1) as a white solid (10 mg, 12%). 1H NMR (400 MHz, CDCl3): 7.88 (d, J = 7.7 Hz, 
1H), 7.73-7.69 (m, 2H), 7.62 (t, J = 7.7 Hz, 1H), 7.57 (td, J = 7.7, 1.6 Hz, 1H), 7.51 (d, J = 7.7 
Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.09 (dt, J = 10.2, 2.0 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.96 
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(s, 1H), 6.55 (dt, J = 9.1, 2.0 Hz, 1H), 4.85 (s, 2H). 13C NMR (100 MHz, CDCl3): 164.0 (d, J = 
247.8 Hz), 158.2, 157.3 (d, J = 12.9 Hz), 139.9 (d, J = 12.7 Hz), 134.6, 134.5, 134.1, 133.6, 
131.2, 129.8, 124.5, 124.1, 121.6, 118.2, 115.5, 104.8 (d, J = 3.2 Hz), 104.7, 102.4 (d, J = 25.3 
Hz), 101.8 (d, J = 26.6 Hz). 49.3. HRMS (ESI) calcd for C20H13FN2NaO3S [M+Na]
+ 403.0523, 
found 403.0528. HPLC tR = 11.9 min, 99.5%. 
3-(3-(1,1-Dioxidobenzo[d]isothiazol-2(3H)-yl)-5-fluorophenoxy)benzonitrile (30). The title 
compound was obtained as described for 22 using 25 (58 mg, 0.21 mmol) and 3-iodobenzonitrile 
(40 mg, 0.17 mmol) as starting materials. The crude product was purified by flash 
chromatography (EtOAc/PE, 3:7) and recrystallized from EtOAc/PE (3:1) to give 30 as a white 
solid (20 mg, 30%). 1H NMR (400 MHz, CDCl3): 7.88 (d, J = 7.8 Hz, 1H), 7.71 (t, J = 7.5 Hz, 
1H), 7.62 (t, J = 7.5 Hz, 1H), 7.53 – 7.43 (m, 3H), 7.35 – 7.28 (m, 2H), 7.00 (dt, J = 10.2, 2.0 
Hz, 1H), 6.95 (s, 1H), 6.48 (dt, J = 9.3, 2.0 Hz, 1H), 4.84 (s, 2H). 13C NMR (100 MHz, CDCl3): 
164.1 (d, J = 247.5 Hz), 158.0 (d, J = 12.7 Hz), 156.7, 139.9 (d, J = 12.8 Hz), 134.6, 133.6, 
131.2, 131.0, 129.8, 127.7, 124.5, 123.6, 122.2, 121.6, 118.0, 114.0, 104.5 (d, J = 3.1 Hz), 101.9 
(d, J = 25.0 Hz), 101.2 (d, J = 26.9 Hz), 49.2. HRMS (ESI) calcd for C20H13FN2NaO3S [M+Na]
+ 
403.0523, found 403.0523. HPLC tR = 12.2 min, 98.6%. 
4-(3-(1,1-Dioxidobenzo[d]isothiazol-2(3H)-yl)-5-fluorophenoxy)benzonitrile (31). The title 
compound was obtained as described for 22 using 25 (74 mg, 0.26 mmol) and 4-
bromobenzonitrile (40 mg, 0.22 mmol) as starting materials. The crude product was purified by 
flash chromatography (EtOAc/PE, 1:3) and recrystallized from EtOAc/PE (3:1) to give 31 as a 
white solid (37 mg, 45%). 1H NMR (400 MHz, CDCl3): 7.88 (d, J = 7.7 Hz, 1H), 7.71 (t, J = 7.7 
Hz, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.63 (t, J = 7.7 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.11 (d, J = 
8.8 Hz, 2H), 7.03 (dt, J = 10.2, 2.0 Hz, 1H), 6.97 (s, 1H), 6.55 (dt, J = 9.1, 2.0 Hz, 1H), 4.84 (s, 
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2H). 13C NMR (100 MHz, CDCl3): 164.1 (d, J = 248.0 Hz), 160.2, 157.2 (d, J = 12.9 Hz), 140.0 
(d, J = 12.8 Hz), 134.6, 134.4, 133.6, 131.2, 129.8, 124.5, 121.7, 118.8, 118.5, 107.2, 105.1 (d, J 
= 3.1 Hz), 102.8 (d, J = 24.8 Hz), 101.6 (d, J = 26.7 Hz), 49.2. HRMS (ESI) calcd for 
C20H13FN2NaO3S [M+Na]
+ 403.0523, found 403.0503. HPLC tR = 12.2 min, 99.2%. 
2-(3-(3-(1,1-Dioxidobenzo[d]isothiazol-2(3H)-yl)-5-fluorophenoxy)phenyl)acetonitrile 
(32). The title compound was obtained as described for 22 using 25 (70 mg, 0.25 mmol) and 3-
bromophenylacetonitrile (40 mg, 0.38 mmol) as starting materials. The crude product was 
purified by flash chromatography (EtOAc/PE, 3:7) and the title compound 32 was recrystallized 
from EtOAc/PE (3:1) as an orange solid (20 mg, 20%). 1H NMR (400 MHz, CDCl3): 7.86 (d, J = 
7.7 Hz, 1H), 7.69 (td, J = 7.7, 1.0 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.40 
(td, J = 1.6, 7.6 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.06 – 7.02 (m, 2H), 6.99 (dt, J = 10.2, 2.1 Hz, 
1H), 6.89 (s, 1H), 6.46 (dt, J = 9.6, 2.1 Hz, 1H), 4.82 (s, 2H), 3.76 (s, 2H). 13C NMR (100 MHz, 
CDCl3): 164.0 (d, J = 246.6), 159.0 (d, J = 12.8), 156.6, 139.5 (d, J = 13.2), 134.7, 133.5, 132.1, 
131.4, 130.8, 129.7, 124.5, 123.7, 121.6, 119.1, 117.5, 104.0 (d, J = 3.1), 101.5 (d, J = 25.0), 
100.6 (d, J = 26.8), 49.3, 23.5. HRMS (ESI) calcd for C21H15FN2NaO3S [M+Na]
+ 417.0680, 
found 417.0667. HPLC tR = 12.0 min, 99.5%. 
2-(3-Fluoro-5-(pyridin-4-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (33). 
The title compound was obtained as described for 22 using 25 (79 mg, 0.28 mmol) and 4-
bromopyridine hydrochloride (46 mg, 0.22 mmol) as starting materials. The crude product was 
purified by flash chromatography (EtOAc/PE, 9:1) to provide 33 as a white solid (34 mg, 40%). 
1H NMR (400 MHz, CDCl3): 8.54 (d, J = 3.9 Hz, 2H), 7.88 (d, J = 7.8 Hz, 1H), 7.71 (t, J = 7.5 
Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 10.2 Hz, 1H), 6.97 (s, 
1H), 6.93 (d, J = 5.5 Hz, 2H), 6.61 (d, J = 9.0 Hz, 1H), 4.84 (s, 2H). 13C NMR (100 MHz, 
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CDCl3): 164.0 (d, J = 248.0), 163.6, 156.2 (d, J = 12.9), 151.7, 139.9 (d, J = 12.9), 134.6, 133.6, 
131.2, 129.8, 124.6, 1221.6, 112.7, 105.5 (d, J = 3.2), 103.4 (d, J = 24.5), 102.0 (d, J = 26.7), 
49.3. HRMS (ESI) calcd for C18H14FN2O3S [M+H]
+ 357.0704, found 357.0717. HPLC tR = 8.6 
min, 98.8%. 
2-(3-Fluoro-5-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (34). 
The title compound was obtained as described for 22 using 25 (75 mg, 0.27 mmol) and 2-
iodopyridine (24 µL, 0.22 mmol) as starting materials. The crude product was purified by flash 
chromatography (EtOAc/PE, 2:3) and the title compound 34 was recrystallized from acetone/PE 
as a white solid (36 mg, 45%). 1H NMR (400 MHz, CDCl3): 8.23 (dd, J = 4.7, 1.4 Hz, 1H), 7.86 
(d, J = 7.6 Hz, 1H), 7.73 (dd, J = 7.6, 1.9 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.59 (t, J = 7.6 Hz, 
1H), 7.49 (d, J = 7.6 Hz, 1H), 7.08 – 7.04 (m, 2H), 7.01 (s, 1H), 6.97 (d, J = 8.3 Hz, 1H), 6.69 
(dt, J = 9.4, 1.8 Hz, 1H), 4.83 (s, 2H). 13C NMR (100 MHz, CDCl3): 163.7 (d, J = 246.3 Hz), 
162.7, 156.2 (d, J = 13.3 Hz), 147.8, 139.8, 139.2 (d, J = 12.8 Hz), 134.8, 133.4, 131.4, 129.6, 
124.5, 121.6, 119.4, 112.1, 106.5 (d, J = 3.2 Hz), 104.3 (d, J = 24.5 Hz), 101.8 (d, J = 26.7 Hz), 
49.3. HRMS (ESI) calcd for C18H14FN2O3S [M+H]
+ 357.0704, found 357.0704. HPLC tR = 11.6 
min, 98.1%. 
2-(3-Iodophenoxy)pyridine (35). A vial was charged with 3-iodophenol (500 mg, 2.27 
mmol), K2CO3 (345 mg, 2.5 mmol), dry DMF (2 mL) and 2-fluoropyridine (196 µL, 2.27 
mmol). The vial was capped and heated at 140 ºC under microwave irradiation for 6 h. The 
reaction was partitioned between water and EtOAc, the aqueous phase was extracted with EtOAc 
(2x). The combined organic phases were washed with brine, dried (Na2SO4) and concentrated. 
The crude product was purified by flash chromatography (EtOAc/PE, 1:9) to give 35 as colorless 
oil that solidified upon standing (416 mg, 62%). 1H NMR (400 MHz, CDCl3): 8.20 (dd, J = 4.9, 
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1.3 Hz, 1H), 7.70 (td, J = 8.3, 1.9 Hz, 1H), 7.55 – 7.48 (m, 2H), 7.16 – 7.09 (m, 2H), 7.02 (dd, J 
= 6.8, 5.4 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H). 13C NMR (100 MHz, CDCl3): 163.2, 154.6, 147.8, 
139.6, 133.7, 130.9, 130.3, 120.7, 119.0, 111.8, 94.0. HRMS (ESI) calcd for C11H9INO [M+H]
+ 
297.9723, found 297.9716. HPLC tR = 12.5 min, 99.8%. 
2-(3-(Pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (36). The title 
compound was obtained as described for 21 using 20 (75 mg, 0.44 mmol) and 35 (158 mg, 0.53 
mmol) as starting materials. The crude product was purified by flash chromatography 
(EtOAc/PE, 1:1) and the title compound (36) was recrystallized from EtOAc/PE (1:1) as a white 
solid (110 mg, 73%). 1H NMR (400 MHz, CDCl3): 8.21 (dd, J = 5.0, 1.3 Hz, 1H), 7.86 (d, J = 
7.5 Hz, 1H), 7.70 (ddd, J = 8.3, 7.4, 2.0 Hz, 1H), 7.65 (td, J = 0.8, 7.5 Hz, 1H), 7.58 (t, J = 7.5 
Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.43 (t, J = 8.1 Hz, 1H), 7.36 (dd, J = 8.2, 1.3 Hz, 1H), 7.21 (t, 
J = 2.1 Hz, 1H), 7.01 (ddd, J = 6.9, 5.0, 0.6 Hz, 1H), 6.98 – 6.92 (m, 2H), 4.85 (s, 2H). 13C NMR 
(100 MHz, CDCl3): 163.4, 155.2, 147.8, 139.6, 138.4, 135.0, 133.2, 131.9, 130.6, 129.5, 124.5, 
121.5, 118.8, 117.0, 115.0, 111.9, 111.8, 49.5. HRMS (ESI) calcd for HRMS (ESI) calcd for 
C18H15N2O3S [M+H]
+ 339.0798, found 339.0787. HPLC tR = 11.2 min, 99.6%. 
2-(3-Bromo-5-chlorophenoxy)pyridine (37). The title compound was obtained as described 
for 35 using 3-bromo-5-chlorophenol (100 mg, 0.48 mmol) and 2-fluoropyridine (41 µL, 0.48 
mmol) as starting materials. The crude product was purified by flash chromatography 
(EtOAc/PE, 1:9) to give 37 as colorless oil that crystallized upon standing (89 mg, 65%). 1H 
NMR (400 MHz, CDCl3): 8.21 (ddd, J = 5.0, 2.0, 0.7 Hz, 1H), 7.74 (ddd, J = 8.3, 7.2, 2.0 Hz, 
1H), 7.34 (t, J = 1.9 Hz, 1H), 7.22 (t, J = 1.9 Hz, 1H), 7.11 (t, J = 1.9 Hz, 1H), 7.07 (ddd, J = 7.2, 
5.0, 0.7 Hz, 1H), 6.96 (dt, J = 8.3, 0.7 Hz, 1H). 13C NMR (100 MHz, CDCl3): 155.2, 147.7, 
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139.8, 135.5, 127.6, 122.9, 122.7, 120.5, 119.5, 112.1. HRMS (ESI) calcd for C11H8BrClNO 
[M+H]+ 283.9472, found 283.9483. HPLC tR = 13.4 min, 98.9%. 
2-(3-Chloro-5-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (38). 
The title compound was obtained as described for 21 using 20 (37 mg, 0.22 mmol) and 37 (75 
mg, 0.26 mmol) as starting materials. The crude product was purified by flash chromatography 
(EtOAc/PE, 3:7) to provide 38 as a colorless oil that crystallized upon standing (50 mg, 61%). 1H 
NMR (400 MHz, CDCl3): 8.22 (ddd, J = 5.0, 1.9, 0.6 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.73 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.69 (td, J = 7.6, 1.1 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.49 (d, J 
= 7.6 Hz, 1H), 7.29 (t, J = 2.0 Hz, 1H), 7.17 (t, J = 2.0 Hz, 1H), 7.06 (ddd, J = 7.2, 5.0, 0.9 Hz, 
1H), 7.00 – 6.95 (m, 2H), 4.85 (s, 2H). 13C NMR (100 MHz, CDCl3): 162.8, 155.6, 147.8, 139.8, 
139.1, 135.9, 134.8, 133.4, 131.5, 129.6, 124.49, 121.6, 119.3, 117.2, 114.5, 112.1, 109.7. 
HRMS (ESI) calcd for C18H14ClNO3S [M+H]
+ 373.0408, found 374.0406. HPLC tR = 12.1 min, 
> 99.9%.  
Computational modeling 
Homology modeling. The sequences of the short isoform of human FFA4 and the nanobody-
stabilized ² 2-adrenoceptor (PDB ID 3P0G)
31 were aligned manually. Homology models of FFA4 
were constructed using Modeller 9.14.32 The FFA4 homology model was imported into 
Maestro,33 preprocessed using the OPLS-2005 force field, added hydrogen atoms and assigned 
partial charges. Hydrogen bond assignment was done at pH = 7.4 using PROPKA.34 Restrained 
minimization was performed until heavy atoms converged to RMSD = 0.3 Å using the OPLS-
2005 force field.  
Ligand Preparation and Docking. All ligands were converted to three-dimensional structures 
in Maestro. MacroModel was used for energy minimization of ligands using the OPLS-2005 
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force field.35 Ligands were prepared using Lig-Prep.36 Ionization states were generated using 
Epik at pH 7.0 ±1.0, and low energy ring conformations were restricted to one per ligand. 
Induced-fit docking studies were performed using the extended sampling protocol as 
implemented in Schrodinger suite 2015-3.37 Ligand conformational sampling was performed 
using default settings. Prime was used to refine residues within 5.0 Å of ligand poses.38  
In vitro assays 
² ‐Arrestin-2 Interaction Assay. Plasmids encoding human or mouse FFA4 or human or 
mouse FFA1 fused at the C-terminal to enhanced yellow fluorescent protein were cotransfected 
into HEK 293 cells with a plasmid encoding ² -arrestin 2 fused to Renilla luciferase. Cells were 
distributed into white 96-well plates 24 h post-transfection and then maintained in culture for 
another 24 h prior to their use. For FFA4, the cells were first washed in Hank’s Balanced Salt 
Solution and then the Renilla luciferase substrate coelenterazine h (2.5 µM) for 15 mins. For the 
final 5 mins of coelentrazine h incubation, the cells were treated with the ligands of interest. For 
FFA1, following cell washing, the cells were firstly incubated with ligands for 30 mins. 15 mins 
prior to the end of the incubation, the cells were treated with coelentrazine h (2.5 µM). All 
incubations were at 37 °C. Luminescence at 535 and 475 nm was then measured using a 
Pherastar FS plate reader and the ratio of luminescence at 535/475 nm used to calculate the 
BRET response.  
FFA1 Calcium Mobilization Assay. 1321N1 cells stably transfected with human FFA1 were 
grown in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) fetal calf serum, 
100 U/mL penicillin, 100 µg/mL streptomycin, and 400 µg/mL G418. Cells were seeded in 96-
well black clear-bottom ninety-six-well microplates at a density of 15,000 cells per well. After 
24 h, the cells were incubated in culture medium containing the Ca2+-sensitive dye Fura2-AM (3 
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mM) for 45 min. Cells were then washed three times in Hanks’ balanced salt solution (HBSS) 
and then allowed to equilibrate for 15 mins before conducting the assay. Fura2 fluorescent 
emission was them measured at 510 nm following excitation at both 340 and 380 nm during the 
course of the experiment using a Flexstation plate reader (Molecular Devices). Ca2+ responses 
were measured as the difference between 340:380 ratios before and after the addition of ligands. 
For antagonism testing, Ca2+ assays were carried out on Flp-In T-REx 293 cell lines, generated to 
inducibly express FFA1 upon treatment with doxycycline. One day prior to conducting the 
experiment, cells were seeded at 50 000 cells/well and allowed to adhere for 3–4 h before the 
addition of 100 ng/ml doxycycline to induce receptor expression. The following day, cells were 
incubated in culture medium containing Fura2-AM (3 mM) for 45 min. Cells were then washed 
three times and then preincubated for 15 min in Hanks’ balanced salt solution (HBSS) 
supplemented with the appropriate ligands to be tested for antagonism. Upon addition of 300 nM 
10, Fura2 fluorescent emission and subsequent Ca2+ responses were measured as described 
above.  
FFA4 Calcium Mobilization Assay. Ca2+ assays were carried out on Flp-In T-REx 293 cell 
lines, generated to inducibly express FFA4 upon treatment with doxycycline. As described 
above, 24 hours prior to conducting the experiment, cells were seeded at 50 000 cells/well in 
black clear-bottom ninety-six-well microplates, allowed to adhere, and then treated with 100 
ng/ml doxycycline overnight to induce receptor expression. The following day, cells were 
incubated in culture medium containing Fura2-AM (3 mM) for 45 min, washed three times in 
HBSS, and then allowed to equilibrate for 15 min. Upon ligand addition, Fura2 fluorescent 
emission and Ca2+ responses were then measured as described above. 
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Data Analysis. BRET and Ca2+ data is presented as the means ± S.E. of 2-4 independent 
experiments, with all data analysis and curve fitting carried out using three parameter sigmoidal 
concentration–response curves generated from the GraphPad Prism software package version 
5.0b (GraphPad, San Diego). 
Animal studies 
Male wild-type mice were obtained from Charles Rivers (Maidstone, Kent, UK). Mice were 
received at five weeks of age. FFA4 (Taconic) knockout mice on a C57Bl6 background were 
maintained in house and were over more than 8 generations crossed to the Bl6 background. They 
were fed on standard laboratory chow (Beekay Feed; B&K Universal Ltd., Hull, UK) until used, 
except that for the studies on diet-induced obesity when FFA4(-/-) mice and wild-type littermates 
were fed from the age of 6 weeks on a high-fat (63% by energy; Open Source D12492, Research 
Diets, New Brunswick, NJ, USA) for 5 months. The bodyweights of the genotypes at the onset 
of dosing (day 0) were 47.1 ± 3.1 g for wild-type mice and 46.0 ± 3.8 g the FFA4(-/-) mice. 
Housing and procedures were conducted in accordance with the UK Government Animal 
(Scientific procedures) Act 1986 and approved by the University of Buckingham Ethical review 
Board. Animals were housed in cages of three on a 12 hour light: dark cycle from 7:00 to 19:00 
at 25-26 °C with ad libitum access to food and water. Animals were killed 3–4 h after the onset 
of the light cycle, by a UK Government Animal Scientific Act 1986 schedule 1 method. 
Oral glucose tolerance. Oral glucose tolerance was measured as described previously.39 
Briefly, mice were fasted for five h before being dosed with glucose (3 g/kg bodyweight, po). 
Blood samples (10 µL) were taken from the tip of the tail after applying a local anesthetic 
(Lignocaine™; Centaur Services, UK), 30 min and immediately before, and 30, 60, 90, 120 and 
180 min after dosing the glucose load. Whole blood was mixed with hemolysis reagent and 
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blood glucose was measured in duplicate using the Sigma Enzymatic (Glucose Oxidase Trinder; 
ThermoFisher Microgenics, UK) colorimetric method and a SpectraMax 250 (Molecular Devices 
Corporation, Sunnyvale, CA, USA).  
Insulin. Plasma insulin levels were measured using a murine insulin ELISA kit (CrystalChem, 
USA) according to the manufacturer’s recommendation. Whole blood was collected into EDTA 
tubes and spun at 3,000 g for 5 min at 4 °C and the plasma stored at −80 °C prior to analysis. 
Plasma samples were assayed in duplicate and the absorbance of both unknowns and standards 
measured using the Spectromax at 450 nm. 
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